A coalition of patient, clinician, and provider groups – including the ALS Association, the American Association for Respiratory Care (AARC), the National Association for Medical Direction of Respiratory Care (NAMDRC), American Association for Homecare (AAHC), and the Council for Respiratory Care (CQRC) – today commend Representatives Morgan Griffith (R-VA) and Peter Welch (D-VT) for introducing legislation to protect Medicare beneficiaries’ access to critical home ventilation therapy. The Safeguarding Medicare Access to Respiratory Therapy (SMART) Act of 2019 would delay the inclusion of ventilators from the Medicare durable medical equipment competitive bidding program for five years, and establish a technical expert panel (TEP) to update that national coverage policies for home mechanical ventilator devices so that they reflect technological advancements and peer-reviewed science.
Richard will always be Dad, Papa, Dick, Your Honor and the patriarch of the family. Somehow I was blessed with the most amazing man as my Father. He taught me the importance of family, love, respect, and commitment.
The ALS Association announced today that Ventec Life Systems is the newest corporate sponsor to commit to helping people with ALS and their caregivers to live their lives to the fullest. Ventec Life Systems has committed to the development and launch of comprehensive respiratory care educational resources to help people living with ALS and their caregivers make informed decisions about their health.
Permobil, the world’s leading manufacturer of power wheelchairs, and the Permobil Foundation have once again joined forces with The ALS Association as a national-level partner to offer support and enhance the quality of life for people living with ALS.
Quantum Rehab, a leading manufacturer of complex rehab power wheelchairs, recently renewed its role as a national partner with The ALS Association, marking the company’s seventeenth year fighting with the Association to make sure people with ALS can live their lives to the fullest. ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Eventually, people with ALS lose the ability to initiate and control muscle movement, which often leads to total paralysis and death within five years of diagnosis. For unknown reasons, veterans are twice as likely to develop ALS as the general population. There is no cure.
An independent research organization reported that donations from the 2014 ALS Ice Bucket Challenge enabled The ALS Association to increase its annual funding for research around the world by 187 percent. During this time, ALS researchers made scientific advances, care for people living with ALS expanded and investment in disease research from the federal government grew.
Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is renewing its Gold Level Sponsorship of the National Walks to Defeat ALS® and Premier Level National ALS Advocacy Conference Sponsorship as well as Platinum Level Sponsorship for initiatives led by The ALS Association Golden West Chapter, including grant funding for care services for people with ALS in the Bay Area.
The ALS Association is pleased to announce the continuation of its national collaboration with Mitsubishi Tanabe Pharma America, Inc. (MTPA), which has resulted in significant support of the Walk to Defeat ALS program, various national conferences and events, and an extensive care grant distributed to The ALS Association chapter network.
The ALS Association, the only national nonprofit fighting amyotrophic lateral sclerosis (ALS) on every front, applauded the Food and Drug Administration’s (FDA) announcement today that it has approved Radicava (edaravone), the first new treatment approved specifically for ALS in 22 years. The FDA approved Radicava less than a year after Mitsubishi Tanabe Pharma Corporation submitted a New Drug Application. There are only two other approved treatments specifically for ALS, Riluzole and Tiglutik.